Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | QTX-2101 |
| Synonyms | |
| Therapy Description |
QTX-2101 is an oral formulation of arsenic trioxide, which potentially induces tumor cell apoptosis (PMID: 40020161, NCI Drug Dictionary) |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| QTX-2101 | SY 2101|SY2101|SY-2101|QTX 2101|QTX2101|ORH-2014|ORH2014|ORH 2014 | QTX-2101 is an oral formulation of arsenic trioxide, which potentially induces tumor cell apoptosis (PMID: 40020161, NCI Drug Dictionary) |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04996030 | Phase I | Arsenic trioxide + QTX-2101 QTX-2101 Arsenic trioxide | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | Suspended | USA | 0 |